RECALL TRACEABILITY THROUGH SERIALIZATION: LEGAL FRAMEWORK AND LIABILITY

1. INTRODUCTION

Recall traceability through serialization is an important regulatory mechanism designed to identify, monitor and track individual pharmaceutical, biotechnology, medical-device and other regulated products throughout the supply chain. Serialization involves assigning a unique identification code to each product unit, enabling manufacturers, distributors, wholesalers, pharmacies and regulatory authorities to determine its origin, manufacturing details, distribution history and final destination.

The principal objective is to ensure that defective, contaminated, counterfeit, substandard or otherwise unsafe products can be rapidly identified and recalled. Serialization also strengthens consumer protection, regulatory accountability, product safety and public-health administration.

2. MEANING AND LEGAL SIGNIFICANCE OF SERIALIZATION

Serialization refers to assigning a unique identification number or machine-readable code to an individual product package. Such identification may include a product code, batch number, manufacturing date, expiry date and unique serial number.

Its legal significance includes:

Identification of defective products and affected batches.

Prevention and detection of counterfeit medicines.

Verification of product authenticity.

Identification of manufacturers, distributors and retailers.

Establishment of supply-chain accountability.

Facilitation of targeted product recalls.

Preservation of evidence for regulatory investigations and compensation proceedings.

Serialization creates an auditable record that enables authorities to identify the products requiring recall instead of unnecessarily withdrawing every product from the market.

3. LEGAL AND REGULATORY FRAMEWORK IN INDIA

The Indian legal framework governing recall traceability is based on pharmaceutical regulation, consumer protection, food safety and product-liability principles.

A. Drugs and Cosmetics Act, 1940

The Act regulates the import, manufacture, distribution and sale of drugs and cosmetics. Its provisions concerning manufacturing standards, misbranded, adulterated and spurious drugs establish the statutory foundation for product-quality enforcement.

B. Drugs Rules, 1945

The Drugs Rules prescribe requirements relating to labelling, manufacturing, packaging and product identification. Amendments introducing QR-code-based identification requirements for specified drug categories strengthen traceability and authentication.

C. Consumer Protection Act, 2019

The Act provides remedies against defective products, manufacturing defects, deficient services and misleading representations. Manufacturers, sellers and service providers may face product-liability proceedings where statutory conditions are satisfied.

D. Food Safety and Standards Act, 2006

Food businesses must maintain appropriate traceability and recall arrangements. The statutory framework supports withdrawal of unsafe food products and protects consumers against contaminated or non-compliant products.

4. LEGAL OBLIGATIONS OF MANUFACTURERS AND DISTRIBUTORS

Manufacturers must establish reliable identification and documentation systems throughout production and distribution.

Their principal obligations include:

Maintaining unique product and batch identification records.

Recording manufacturing and packaging information.

Maintaining distribution and supply-chain documentation.

Investigating complaints and quality-related incidents.

Identifying affected products when safety risks emerge.

Notifying appropriate regulatory authorities.

Initiating recalls within applicable legal requirements.

Maintaining records demonstrating recall effectiveness.

Distributors, wholesalers and retailers must cooperate with recall instructions, preserve relevant transaction records and prevent further distribution of recalled products.

5. RECALL TRACEABILITY AND PRODUCT LIABILITY

Serialization is particularly important when determining responsibility for defective products. A traceability record may establish the manufacturer, distributor, batch, destination and movement of a particular product.

Failure to maintain accurate records can create evidentiary difficulties and may support allegations of regulatory non-compliance or negligence, depending on the circumstances.

However, serialization alone does not establish that a product is safe. Manufacturers must also maintain quality-control systems, appropriate testing, pharmacovigilance and post-market surveillance.

6. IMPORTANT JUDICIAL PRECEDENTS AND CASE LAWS

The following judgments provide relevant direct and analogous judicial authority. Indian courts have discussed serialization in pharmaceutical supply chains, although not every judgment establishes a binding legal rule specifically governing serialization.

1. Glenmark Pharmaceuticals Ltd. v. Sanjeevni Medicos (Delhi High Court, 2023)

DIRECT JUDICIAL DISCUSSION OF SERIALIZATION

This is particularly important because the Delhi High Court specifically considered serialization and traceability in connection with counterfeit pharmaceutical products. The dispute concerned counterfeit TELMA and TELMA-AM medicines entering the distribution chain.

The Court highlighted the importance of pharmaceutical supply-chain integrity and observed that serialization could help identify and trace medicines throughout distribution channels. It also emphasized the need for effective records and cooperation with investigations.

Legal principle: Serialization is an important mechanism for combating counterfeit medicines and protecting public health.

2. State of Haryana v. Brij Lal Mittal (1998) 5 SCC 343

DIRECT ANALOGOUS AUTHORITY

The Supreme Court considered prosecution arising from the distribution of drugs that were allegedly adulterated and not of standard quality. The judgment examined the statutory responsibilities of persons involved in pharmaceutical manufacturing and distribution.

Legal principle: Pharmaceutical regulatory violations can attract criminal liability, subject to the statutory requirements governing the particular accused person's responsibility.

3. M.C. Mehta v. Union of India (1987) 1 SCC 395

ANALOGOUS AUTHORITY

The Supreme Court established the principle of absolute liability for enterprises engaged in hazardous or inherently dangerous activities. The judgment strengthened the responsibility of enterprises to protect the public from industrial hazards.

Legal principle: Enterprises cannot disregard public safety obligations when their activities create serious risks. This principle supports stringent accountability for unsafe pharmaceutical manufacturing and distribution.

4. Indian Medical Association v. V.P. Shantha (1995) 6 SCC 651

ANALOGOUS AUTHORITY

The Supreme Court examined the applicability of consumer-protection legislation to medical services. It clarified the circumstances in which healthcare services fall within consumer-law remedies.

Legal principle: Consumer protection provides an important avenue for addressing deficiencies and injuries arising from healthcare-related services. This supports the broader consumer-protection objectives underlying pharmaceutical traceability.

5. Spring Meadows Hospital v. Harjol Ahluwalia (1998) 4 SCC 39

ANALOGOUS AUTHORITY

The Supreme Court considered medical negligence and compensation arising from deficient healthcare services. The judgment recognized the importance of accountability where negligence causes injury to patients.

Legal principle: Healthcare-related negligence can attract compensation liability. In pharmaceutical recall disputes, inadequate identification, delayed warnings or failure to address known product risks may become relevant evidence of negligence.

6. Donoghue v. Stevenson [1932] AC 562

FOUNDATIONAL ANALOGOUS AUTHORITY

The House of Lords established the modern negligence principle requiring manufacturers to exercise reasonable care toward ultimate consumers who may be affected by defective products.

Legal principle: Manufacturers owe consumers a duty of care regarding product safety. Serialization and recall traceability can help demonstrate whether manufacturers exercised appropriate care in identifying and responding to product defects.

7. RECENT REGULATORY DEVELOPMENTS IN INDIA

India has progressively strengthened pharmaceutical traceability requirements.

2022: QR-code requirements were introduced for active pharmaceutical ingredients under the Drugs Rules, 1945.

2023: QR-code or barcode requirements for specified top 300 drug brands under Schedule H2 became effective from 1 August 2023.

2024: CDSCO published the revised Guidelines on Recall and Rapid Alert System for Drugs, including biologicals and vaccines, requiring compliance by relevant licensees and supply-chain stakeholders.

2026: The Government announced an expansion of QR-code-based traceability to vaccines, antimicrobials, narcotic and psychotropic drugs and anti-cancer medicines, with phased implementation dates of 1 July 2027 and 1 July 2028, depending on the category.

These developments demonstrate the increasing importance of digital authentication and supply-chain accountability in pharmaceutical regulation.

QMS/37/Guideline/2024+3

8. CONSEQUENCES OF NON-COMPLIANCE

Failure to maintain proper serialization and recall traceability arrangements may result in:

Regulatory investigations and inspections.

Suspension or cancellation of manufacturing licences where legally justified.

Stop-production and stop-distribution directions.

Seizure of suspected counterfeit or substandard products.

Criminal prosecution under applicable provisions of the Drugs and Cosmetics Act, 1940.

Consumer compensation and product-liability proceedings.

Reputational damage and loss of commercial confidence.

The precise consequences depend on the nature of the violation, applicable statutory provisions and evidence establishing responsibility.

9. PRACTICAL COMPLIANCE REQUIREMENTS

Pharmaceutical and biotechnology companies should adopt the following measures:

Implement unique product identification and serialization systems.

Maintain accurate batch-level and distribution-level records.

Ensure integration between manufacturing, warehousing and distribution databases.

Establish written product-recall procedures.

Maintain records of products dispatched, recovered and destroyed.

Conduct periodic mock-recall exercises.

Ensure prompt communication with distributors, pharmacies and regulators.

Preserve electronic records for regulatory inspection and legal proceedings.

Investigate discrepancies in serial numbers and suspicious product movements.

10. CONCLUSION

Recall traceability through serialization is an essential component of modern pharmaceutical governance and consumer protection. It enables manufacturers and regulatory authorities to identify defective products, trace their distribution history and initiate targeted recalls before further harm occurs.

The Glenmark Pharmaceuticals Ltd. v. Sanjeevni Medicos judgment is particularly significant because the Delhi High Court expressly recognized the public-health importance of serialization and pharmaceutical supply-chain traceability.

Together with the Drugs and Cosmetics Act, 1940, the Drugs Rules, 1945, consumer-protection legislation and applicable recall guidelines, serialization strengthens regulatory accountability and product safety. Ultimately, an effective serialization system is not merely a technological arrangement but an important instrument for protecting patients, establishing responsibility and ensuring confidence in the pharmaceutical supply chain.

Important legal distinction: The Glenmark judgment is the strongest directly relevant Indian judicial authority discussed here. The other five cases are analogous authorities on pharmaceutical regulation, negligence, consumer protection and enterprise responsibility; they should not be cited as decisions mandating serialization itself.